GSK2231395A

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Haemophilus InfluenzaeStreptococcus Pneumoniae

Phase 1

Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

CompletedNCT00814489

GlaxoSmithKlineHaemophilus Influenzae, Streptococcus Pneumoniae

Start: 2009-01-08End: 2010-06-10Updated: 2018-08-08

Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine

TerminatedNCT00849069

GlaxoSmithKlineHaemophilus Influenzae, Streptococcus Pneumoniae

Start: 2009-03-12End: 2009-04-07Target: 30Updated: 2017-10-31

Related Papers

Safety, Immunogenicity, and Antibody Persistence following an Investigational Streptococcus pneumoniae and Haemophilus influenzae Triple-Protein Vaccine in a Phase 1 Randomized Controlled Study in Healthy Adults

Clinical and Vaccine Immunology2013-10-3138 citations